Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) just unveiled an update.
On June 24, 2025, MAIA Biotechnology, Inc. entered into a stock purchase agreement with Prevail Partners, LLC to issue and sell shares worth $587,905. The agreement includes an upfront payment and 36 equal tranche payments, with a minimum share price set at $1.74. The proceeds will be used to fund a Phase 3 study evaluating a combination treatment for advanced non-small cell lung cancer.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative treatments for cancer. The company is engaged in conducting advanced clinical trials, particularly in the area of non-small cell lung cancer.
Average Trading Volume: 295,343
Technical Sentiment Signal: Sell
Current Market Cap: $50.92M
Learn more about MAIA stock on TipRanks’ Stock Analysis page.